OrthoPediatrics corp Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $252.7M+23.4% YoYTTM through 30 Jun 2026
Net Income -$39.7MTTM through 30 Jun 2026
Free Cash Flow -$1.8MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 73.1% |
| EBITDA Margin | -3.0% |
| Operating Margin | -16.6% |
| Net Margin | -15.7% |
Returns
-11.4%ROE
-7.8%ROA
Balance Sheet Health
Debt / Equity0.31x
Current Ratio4.78x
Net Debt$43.8M
Cash & Equivalents$17M
Quality Metrics
Altman Z-Score2.09
Piotroski F-Score5 / 9
FCF Margin-0.7%
Rule of 404.2
Earnings-Beat Rate100.0%
Multi-Year Trend
RevenueFY2025: $236.3M
Diluted EPS-$1.68TTMFY2025: $-1.69
Dividend
No dividend
Capital Allocation
R&D Spend$9.1M
Capex Intensity3.7%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Trauma and Deformity | $166.3M | +14.6% | View detailsExpected to continue gaining market share driven by new product launches and clinic expansions. |
| Scoliosis | $66M | +19.6% | View detailsStrong growth momentum supported by international expansion and direct sales model transitions. |
| Sports Medicine/Other | $4M | -9.1% | View detailsDeepening customer relationships through capital-efficient growth platforms. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.